CTI BioPharma Corp. (NASDAQ:CTIC) has analysts on the Bullish side this week.

January 14, 2018 - By Richard Conner

 CTI BioPharma Corp. (NASDAQ:CTIC) has analysts on the Bullish side this week.

CTI BioPharma Corp. (NASDAQ:CTIC) Ratings Coverage

Among 2 analysts covering CTI BioPharma Corp (NASDAQ:CTIC), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. CTI BioPharma Corp had 3 analyst reports since August 15, 2015 according to SRatingsIntel. WallachBeth Capital downgraded CTI BioPharma Corp. (NASDAQ:CTIC) on Monday, November 9 to “Hold” rating. The rating was maintained by Roth Capital with “Buy” on Saturday, August 15. Below is a list of CTI BioPharma Corp. (NASDAQ:CTIC) latest ratings and price target changes.

12/09/2017 Broker: Jefferies Rating: Buy New Target: $7.5 Initiates Coverage On

The stock increased 3.96% or $0.13 during the last trading session, reaching $3.41. About 362,376 shares traded or 141.98% up from the average. CTI BioPharma Corp. (NASDAQ:CTIC) has declined 4.09% since January 14, 2017 and is downtrending. It has underperformed by 20.79% the S&P500.

CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. The company has market cap of $146.52 million. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in the European Union. It currently has negative earnings. The firm is also developing Pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase Phase III clinical trials for the treatment of myelofibrosis.

More notable recent CTI BioPharma Corp. (NASDAQ:CTIC) news were published by: Seekingalpha.com which released: “CTI Biopharma’s Pacritinib: Where We Stand Today” on August 14, 2017, also Seekingalpha.com with their article: “CTI BioPharma Loses Strength As The Company Faces Sharp Revenue Decline” published on December 20, 2017, Prnewswire.com published: “CTI BioPharma Announces Top-Line Results From PERSIST-2 Phase 3 Trial Of …” on August 29, 2016. More interesting news about CTI BioPharma Corp. (NASDAQ:CTIC) were released by: Fool.com and their article: “Why CTI BioPharma Corp. Stock Popped Today” published on January 05, 2017 as well as Seekingalpha.com‘s news article titled: “CTI BioPharma’s (CTIC) CEO Richard Love on Q1 2017 Results – Earnings Call …” with publication date: May 04, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.